Comparison of thrombosis risk in patients undergoing purified and non-purified islet cell transplantation
Pancreatology · 2025
DOI: 10.1016/j.pan.2025.04.018 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Pancreatology, 2025. Verfasst von Victoria Ruvkun und 4 weiteren Autor:innen. Beteiligte Einrichtung: Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA. Hauptthemen laut MEDLINE: Islets of Langerhans Transplantation, Thrombosis, Venous Thrombosis. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: To investigate the thrombosis risk and adverse bleeding events in patients who received purified vs. non-purified islet cell autotransplants (IAT). METHODS: We performed a retrospective cohort study evaluating the rate of portal vein thrombosis (PVT), adverse bleeding events, and premature heparin discontinuation in purified and non-purified IAT patients at our center between 2013 and 2022. RESULTS: The incidence of PVT formation was 0 % in the purified group (23 patients) and 4.2 % in the non-purified group (48 patients). Patients in the purified islet group received lower intra-operative heparin dosing compared to patients in the non-purified group (3157units vs 2657units, p = 0.03), but both groups received similar post-operative heparin dosing (505units vs. 437units, p = 0.55). Non-purified patients were on heparin for significantly fewer days than purified patients (1.6 days vs. 3.2 days, p < 0.01). There was no difference in adverse bleeding events that resulted in premature heparin discontinuation (39.1 % vs. 62.5 %, p = 0.08) nor blood transfusion requirements (34.8 % vs. 41.7 %, p = 0.58) between the purified and non-purified groups. However, patients in the purified group had higher rates of reoperation due to rebleeding compared with the non-purified group (17.4 % vs 0 %, p < 0.01). CONCLUSIONS: While PVT is a relatively rare event in both purified and non-purified IAT when peri-operative and post-operative full-dose heparinization is administered, there remains a clinical difference in PVT formation between purified and non-purified IATs. Although bleeding risk may potentially be mitigated by a reduction in the duration of full dose heparinization without a corresponding risk in PVT rate, further investigation is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
- Section of General Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
- Section of Endocrinology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
- Section of General Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA. Electronic address: timothy.b.gardner@hitchcock.org.
Zitieren
APA
Ruvkun, V., Smith, K. D., Chaidarun, S. S., Fischer, D. A., & Gardner, T. B. (2025). Comparison of thrombosis risk in patients undergoing purified and non-purified islet cell transplantation. Pancreatology. https://doi.org/10.1016/j.pan.2025.04.018
Vancouver
Ruvkun V, Smith KD, Chaidarun SS, Fischer DA, Gardner TB. Comparison of thrombosis risk in patients undergoing purified and non-purified islet cell transplantation. Pancreatology. 2025. doi:10.1016/j.pan.2025.04.018
BibTeX
@article{Ruvkun2025,
author = {Ruvkun, Victoria and Smith, Kerrington D and Chaidarun, Sushela S and Fischer, Dawn A and Gardner, Timothy B},
title = {Comparison of thrombosis risk in patients undergoing purified and non-purified islet cell transplantation},
journal = {Pancreatology},
year = {2025},
doi = {10.1016/j.pan.2025.04.018}
}
EUVIMED